Még nem toboroz
A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients
NCT07936422· 2. fázis· Centre Leon Berard· Forrás
Még nem toboroz
A clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
2024-512340-32-01· 3. fázis· Novartis Pharma AG· Forrás
Még nem toboroz
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· 1. fázis· Eli Lilly and Company· Forrás
Még nem toboroz
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
NCT07857486· 2. fázis· Institut Paoli-Calmettes· Forrás
Toboroz
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· 1/2. fázis· Daiichi Sankyo· Forrás
Még nem toboroz
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· 2. fázis· UNICANCER· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· 1/2. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
2025-524488-18-00· 2. fázis· Astellas Pharma Global Development Inc.· Forrás
Toboroz
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00· 1. fázis· Janssen Cilag International· Forrás
Még nem toboroz
Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG
2025-523610-83-00· 4. fázis· Institut Gustave Roussy· Forrás
Toboroz
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00· 1. fázis· Novartis Pharma AG· Forrás
Toboroz
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655· 1. fázis· Pfizer· Forrás
Toboroz
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360· 2. fázis· CSL Behring· Forrás
Toboroz
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
NCT06225505· Institut Curie· Forrás
Contact: Florence DALENC, MD
Még nem toboroz
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2025-521090-14-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Eleonora De Maio (principal investigator)
Toboroz
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· 3. fázis· Eli Lilly and Company· Forrás
Contact: Damien POUESSEL (principal investigator)
Toboroz
Momelotinib in VEXAS syndrome
2024-519779-24-00· 2. fázis· Groupe Francophone Des Myelodysplasies· Forrás
Toboroz
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845· 2. fázis· AbbVie· Forrás
Toboroz
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
NCT07243470· 1/2. fázis· Centre Leon Berard· Forrás
Toboroz
Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un cancer du sein métastatique (TDXdose)
2025-522656-68-00· 4. fázis· Oncopole Claudius Regaud· Forrás
Toboroz
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2024-514152-32-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Toboroz
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016· 1. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960· 1/2. fázis· AbbVie· Forrás
Toboroz
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors
NCT06660654· 2. fázis· Daiichi Sankyo Inc.· Forrás
Toboroz
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?
2024-511435-10-00· 1. fázis· Captor Therapeutics S.A.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229· 1. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· 3. fázis· Genmab· Forrás
Meghívásos bevonás
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509· 1. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
NCT06435429· 3. fázis· Jazz Pharmaceuticals Ireland Limited· Forrás
Toboroz
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
NCT06126588· 2. fázis· Central Hospital, Nancy, France· Forrás
Fut, nem toboroz
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomas
2024-514875-16-00· 2. fázis· Oncopole Claudius Regaud· Forrás
Fut, nem toboroz
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789· 3. fázis· SynOx Therapeutics Limited· Forrás
Toboroz
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680· 1/2. fázis· Regeneron Pharmaceuticals· Forrás
Még nem toboroz
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients
NCT03212742· 1. fázis· Centre Francois Baclesse· Forrás
Fut, nem toboroz
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
2023-509566-38-00· 1/2. fázis· Boehringer Ingelheim International GmbH· Forrás
Toboroz
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
NCT06195709· 3. fázis· Institut Curie· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245· 1. fázis· Vividion Therapeutics, Inc.· Forrás
Contact: Study Director
Fut, nem toboroz
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
NCT05753384· 3. fázis· Poitiers University Hospital· Forrás
Fut, nem toboroz
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
NCT05889221· 2. fázis· Poitiers University Hospital· Forrás
Fut, nem toboroz
SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer
NCT05826509· 2. fázis· Institut Claudius Regaud· Forrás
Toboroz
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139· 1/2. fázis· Eli Lilly and Company· Forrás
Showing 50 of 72.